Need professional-grade analysis? Visit stockanalysis.com
$6.38B
N/A
N/A
N/A
Kymera Therapeutics Inc (KYMR) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $88.07, up 0.41% from the previous close.
Over the past year, KYMR has traded between a low of $28.14 and a high of $95.03. The stock has gained 186.9% over this period. It is currently 7.3% below its 52-week high.
Kymera Therapeutics Inc has a market capitalization of $6.38B.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Side-by-side comparison against top Healthcare peers.